Nelianne Verkaik

Nelianne Verkaik is a researcher at Erasmus MC in the Department of Medical Microbiology & Infectious Diseases. Her work focuses on antimicrobial resistance, infection control, and the management of device-related infections, particularly in critical care settings. She is actively involved in major research collaborations such as the DOLPHIN investigators and the SWAB Working Group Surveillance of Antimicrobial Resistance.

Her research interests lie at the intersection of clinical microbiology and public health, with a strong emphasis on antibiotic sensitivity, carbapenemase-producing organisms, and the epidemiology of multidrug-resistant pathogens. A significant portion of her recent work investigates the spread of NDM-producing bacteria from Ukraine into Europe, highlighting the role of patient transfers in cross-border dissemination of resistant strains.

The most recent articles reflect a consistent focus on optimizing antimicrobial therapy, assessing resistance patterns, and improving outcomes in critically ill patients. Her studies frequently employ retrospective analyses, genomic sequencing, and large-scale surveillance data to inform infection prevention strategies and antimicrobial stewardship programs.

Scientific Awards:

• No scientific awards mentioned in the provided text.

Advising and Grants:
There is no explicit mention of student advising or grant funding in the provided information. However, her participation in multi-center studies such as the DOLPHIN trial suggests involvement in significant collaborative research projects, likely supported by external funding. She contributes as a key researcher in national and international efforts to monitor and combat antimicrobial resistance.

Labs, Teams, and Networks:
Dr. Verkaik collaborates extensively within the SWAB Working Group Surveillance of Antimicrobial Resistance and the DOLPHIN investigators. These networks involve multiple institutions across Europe and focus on antimicrobial resistance surveillance, precision dosing trials, and outbreak investigations. Her research leverages data from electronic health records, laboratory networks, and genomic surveillance systems.